Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

SAMe 400 Ingredients & Drug Interactions

by Jarrow Formulas

Tablet Or Pill Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

SAMe 400 is a dietary supplement by Jarrow Formulas with 1 active ingredient. Its ingredients are commonly taken for depression, osteoarthritis joint pain, liver conditions.Based on those ingredients, 189 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are S-Adenosyl Methionine. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of SAMe 400 by Jarrow Formulas

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 1 of its 1 active ingredient.
  • “S-Adenosyl Methionine” is listed as a grouped ingredient — the label gives one combined amount (400 mg) without saying how much of each component you get.

SAMe 400 contains one active ingredient: SAMe Tosylate Disulfate, a form of S-Adenosyl Methionine, a compound your body makes naturally and uses in many chemical reactions. Each tablet delivers 400 mg of this ingredient.

The product also includes several inactive ingredients—microcrystalline cellulose, hypromellose acetate succinate, stearic acid, triethyl citrate, riboflavin, glyceryl behenate, magnesium stearate, silicon dioxide, mannitol, and sodium starch glycolate—that help form and preserve the tablet.

Does it work?

Strong evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Strong

Clinical evidence supports at least one of this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: SAMe supplement for cellular health.
  • We looked for evidence on: Depression, Osteoarthritis, Fibromyalgia, Aging, Alcohol-related liver disease, Cirrhosis — and 4 related terms.
  • The strongest evidence on file: Same is rated "Likely Effective" for Osteoarthritis (Natural Medicines).
  • Also on file: Same is rated "Possibly Effective" for Cholestasis, Depression.
  • Also on file: Same is rated "Insufficient Reliable Evidence To Rate" for Alcohol-related liver disease, Cancer-related fatigue, Cirrhosis, Fibromyalgia.

The evidence for SAMe is strongest for osteoarthritis, where it's rated as likely effective—meaning solid scientific support exists for its use. For depression, the data shows it's possibly effective, so it may help some people, but the evidence is less complete.

There's also possibly effective evidence for cholestasis, a liver condition. For Alzheimer disease and ADHD, we have insufficient reliable evidence to rate its effectiveness, so we can't yet say whether it works for those purposes based on the data we hold.

The evidence, ingredient by ingredient Same

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

SAMe is generally well tolerated when you take it at normal doses, though side effects become more common at higher doses. The most frequent ones are stomach upset—nausea, diarrhea, constipation, vomiting, flatulence—plus dizziness, headache, dry mouth, insomnia, and nervousness.

Some people report rash, itching, or transient hair loss. An important caution: SAMe may trigger mania in people with bipolar disorder, so if you have bipolar disorder, use it only under your doctor's or pharmacist's supervision.

Safety data overall is limited, so professional guidance is important.

Side effects, ingredient by ingredient Same

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Same.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: Parkinson's medications.
  • For scale: 189 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking SAMe 400, double-check any serotonergic drugs you're on—antidepressants, anti-anxiety medications, migraine drugs like triptans, and certain pain relievers. Also check if you take levodopa for Parkinson disease.

These are Moderate-severity interactions. Run your full medication list through the search tool on this page to be sure.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with clinical evidence supporting its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

If you have osteoarthritis, SAMe has solid evidence behind it. If you're considering it for depression, the evidence is less established—talk with your pharmacist about whether it fits your situation.

Anyone taking serotonergic medications (antidepressants, migraine drugs) or levodopa should check with a pharmacist before starting, because the interaction risk is real. If you have bipolar disorder, get professional guidance before using this product.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 1 active ingredient matched to our full ingredient reviews (monographs). Based on the product label dated May 23, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about SAMe 400, straight from the product label.

Brand Jarrow Formulas
Barcode (UPC) 790011200420
Net contents 60 Tablet(s)
Market status On market
Date entered into DSLD May 23, 2024
DSLD ID 307732
Product type Non-nutrient/non-botanical
Supplement form Tablet Or Pill
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Women (not pregnant or lactating), No Allergies, Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for SAMe 400 by Jarrow Formulas, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Tablet(s)
Maximum serving Sizes:
1 Tablet(s)
Servings per container
60
UPC/BARCODE
790011200420
IngredientAmount% DV
S-Adenosyl Methionine400 mg--
SAMe Tosylate Disulfate800 mg--

Other ingredients: Microcrystalline Cellulose, Hypromellose Acetate Succinate, Stearic Acid, Triethyl Citrate, Riboflavin, Glyceryl Behenate, Magnesium Stearate, Silicon Dioxide, Mannitol, Sodium Starch Glycolate

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Naturally Derived SAMe 400 Jarrow Formulas SAMe 400 provides a full 400 mg SAMe (net yield) from 800 mg of SAMe tosylate disulfate.

With more of the Biologically Active S,S than R,S Form Found in all living cells, SAMe is a metabolite of methionine (an essential amino acid). SAMe is a chiral molecule consisting of two forms: (S,S) SAMe and (R,S) SAMe. The biologically active form is the (S,S) structure, while the (R,S) structure is biologically inactive. SAMe supports: Brain Metabolism and Mood SAMe methylation reactions are involved in the synthesis of phosphatidylcholine, a substantial constituent of grey matter within the brain and cellular membranes. It has also been proposed to be involved in the formation or metabolism of neurotransmitters, which helps to support a balanced mood. Joint Health SAMe supports the production of healthy connective tissue through transsulfuration. In this transsulfuration process, critical components of connective tissue known as glycosaminoglycans (GAGs), including glucosamine and chondroitin, are sulfated by SAMe metabolites to yield sulfated GAGs, such as glucosamine sulfate and chondroitin sulfate, the building blocks of cartilage. Liver Function SAMe supports the synthesis of glutathione (GSH), which is critical for antioxidant defenses and liver functions including phase II detoxification.

Naturally derived SAMe 400 S-adenosyl methionine Active S,S form Extra strength

Jarrow Formulas SAMe 400 is foil blister-packed to maximize stability and provides 400 mg S-Adenosyl Methionine derived from 800 mg of SAMe Tosylate Disulfate.

400 mg (net yield) SAMe from 800 mg SAMe tosylate disulfate Enteroguard coating

EnteroGuard is a proprietary cellulose-based, food-grade, pH-sensitive enteric coating that resists stomach acid and disintegrates in the less acidic pH of the upper intestines, where the SAMe is made available for absorption.

Formulation

SAMe 400 is manufactured under low temperature and low humidity and is enteric-coated to ensure a biologically active product.

Jarrow Formulas SAMe is made by microbiological fermentation and processed without chemical solvents to preserve 68-80% (S,S) SAMe.

Vegan

Extra strength Supports balanced mood, joint health, and liver function In foil blister pack

Gluten free

No wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts or sesame.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Suggested/Recommended/Usage/Directions

Suggested Use: Adults take 1 tablet once a day on an empty stomach or as directed by your qualified healthcare professional.

Precautions

Warning: Do not use if pregnant or nursing.

Individuals with Parkinson’s disease, bi-polar disorder, or manic depression should not use this product. May cause gastrointestinal upset in some persons.

Consult a healthcare professional before using this product if you are under the age of 18, are taking medication (antidepressants, selective serotonin re-uptake inhibitors (SSRIs) and MAO inhibitors) or have a medical condition; if adverse reactions occur, discontinue use. Keep out of the reach of children.

Consult a healthcare professional before using this product if you are under the age of 18, are taking medication (antidepressants, selective serotonin re-uptake inhibitors (SSRIs) and MAO inhibitors) or have a medical condition; if adverse reactions occur, discontinue use.

Do not use if safety seal or blister is broken, damaged or missing.

Storage

Store in a cool, dry place.

FDA Statement of Identity

Dietary Supplement

Brand IP Statement(s)

Copyright 2023 Jarrow Formulas

General Statements

Mood support

See for yourself

SAMe 400 by Jarrow Formulas label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in SAMe 400 by Jarrow Formulas

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 Tablet(s) Dosage formTablet Or Pill Servings per container60 Amounts shown are per serving.

S-Adenosyl Methionine

Interacts with
189 drugs
400 mg per serving

SAM-e is a compound your body makes naturally that is sold as a supplement, most often for depression and osteoarthritis. Some research suggests it ma...

S-Adenosyl Methionine monograph & interactions

Other (inactive) ingredients: Microcrystalline Cellulose, Hypromellose Acetate Succinate, Stearic Acid, Triethyl Citrate, Riboflavin, Glyceryl Behenate, Magnesium Stearate, Silicon Dioxide, Mannitol, Sodium Starch Glycolate. These complete the product’s ingredient list but are not active constituents.

Interaction report

SAMe 400 by Jarrow Formulas Drug Interactions

Want to check YOUR meds against SAMe 400?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
189Drugs
189 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in SAMe 400 with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

S-Adenosyl Methionine2 drug types · 189 drugs

Levodopa

SAMe might reduce the effectiveness of levodopa.
SAMe methylates levodopa, which might reduce its effectiveness for treating Parkinson disease.

Likelihood Possible Evidence D
Serotonergic Drugs

Taking SAMe with serotonergic drugs might increase the risk of serotonin syndrome and other serotonergic side effects.
SAMe has serotonergic effects. Theoretically, combining serotonergic drugs with SAMe might increase the risk of serotonergic side effects, including serotonin syndrome and cerebral vasoconstrictive disorders. In one case report, SAMe 100 mg intramuscularly was given daily with clomipramine (Anafranil) 25 mg per day. When the clomipramine dose was increased to 75 mg per day the patient experienced serotonin syndrome about 48-72 hours later, requiring hospitalization.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for SAMe 400, from the product label.

Jarrow Formulas

See all Jarrow Formulas products
Name
Jarrow Formulas, Inc.
City
Sherman Oaks
State
CA
ZipCode
91403
Phone Number
1-866-459-4154
Web Address
www.Jarrow.com
Pharmacist Counseling Corner

SAMe 400 by Jarrow Formulas: Common Questions

Does SAMe 400 by Jarrow Formulas interact with any medications?
Yes. Based on its ingredients, SAMe 400 has a known interaction with 189 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
SAMe 400 contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
What is SAMe and why would I take it?
SAMe is S-Adenosyl Methionine, a compound your body makes naturally. It's involved in many chemical reactions in your cells. The strongest evidence supports using it for osteoarthritis; there's also possibly effective evidence for depression and a liver condition called cholestasis.
Can I take this if I'm on an antidepressant?
Not without checking with your pharmacist first. SAMe and antidepressants can both affect serotonin, and combining them carries a Moderate risk of serotonin syndrome—a potentially serious condition. Your pharmacist can review your specific medication and advise whether it's safe for you.
What side effects might I get?
The most common are stomach-related: nausea, diarrhea, constipation, vomiting, and bloating. You might also experience dizziness, headache, dry mouth, insomnia, or nervousness. Higher doses make side effects more likely. If you have bipolar disorder, there's a risk it could trigger a manic episode.
How much SAMe is in each tablet?
Each tablet of SAMe 400 contains 400 mg of SAMe Tosylate Disulfate.
Is it safe to take during pregnancy or while breastfeeding?
We don't have enough safety data to say whether it's safe in pregnancy or while breastfeeding. Talk with your doctor or pharmacist for personalized advice based on your individual situation.
Does this product have fillers?
Yes, the tablet includes several inactive ingredients that help form and preserve it: microcrystalline cellulose, stearic acid, magnesium stearate, silica, and others.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if SAMe 400 is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

SAMe 400 label
Sources

Sources & How We Checked

SAMe 400's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 31 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Same 31 references
  1. Perna AF, Castaldo P, Ingrosso D, et al. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999;12:230-40.
  2. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9. PubMed
  3. Iruela LM, Minguez L, Merino J, Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993;150:522. PubMed
  4. Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11.
  5. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62. PubMed
  6. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5. PubMed
  7. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6. PubMed
  8. Domljan Z, Vrhovac B, Durrigl T, Pucar I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-33.
  9. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94. PubMed
  10. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-50.
  11. Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40:111-23. PubMed
  12. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416. PubMed
  13. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52. PubMed
  14. Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990;37:122-5.
  15. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. PubMed
  16. Charlton CG, Crowell B Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43:423-31..
  17. Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7. PubMed
  18. Arnold O, Saletu B, Anderer P, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005; PubMed
  19. Nelson JC. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. (Editorial). Am J Psychiatry 2010;167:889-91.
  20. Kim J, Lee EY, Koh EM, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther 2009; PubMed
  21. Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl 4):90-100. DOI
  22. Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson's disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48(1):154-60.
  23. Pancheri P, Scapicchio P, Delle Chiaie R. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuro PubMed
  24. Medici V., Virata M. C., Peerson J. M., Stabler S. P., French S. W., Gregory J. F. III, Albanese A., Bowlus C. L., Devaraj S., Panacek E. A., Richards J. R., Halsted C. H. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, ra
  25. Chitiva, H., Audivert, F., and Alvarez, C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report. J.Nerv.Ment.Dis. 2012;200(1):99-101. PubMed
  26. Carney, M. W., Edeh, J., Bottiglieri, T., Reynolds, E. M., and Toone, B. K. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol. 1986;9(4):379-385. PubMed
  27. Miccoli, L., Porro, V., and Bertolino, A. Comparison between the antidepressant activity and of S- adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 1978;33 (3):243-255.
  28. Bacci, Ballerini F., Lopez, Anguera A., Alcaraz, P., and Hernandez, Reyes N. [SAMe in the management of postconcussional syndrome]. Medicina Clinica (Barc.) 1983;80(4):161-164.
  29. Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. Advances in Biochemical Psychopharmacology 1982;32:151-6.
  30. Capretto C, Cremona C, and Canaparo L. A double-blind controlled study of S-adenosylmethionine (SAMe) v. ibuprofen in gonarthrosis, coxarthrosis and spondylarthrosis. Clin Trials J 1985;22(1):15-24.
  31. Ancarani E, Biondi B, Bolletta A, et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res 1993;54(6):680-6. DOI

See these in context on the Same monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring